Go Pro
NASDAQ:MBIO

Mustang Bio Q2 2026 Earnings Report

Mustang Bio logo
$0.52 -0.01 (-1.10%)
As of 09/25/2026 03:14 PM Eastern

Mustang Bio EPS Results

Actual EPS
N/A
Consensus EPS
-$140.00
Beat/Miss
N/A
One Year Ago EPS
N/A

Mustang Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mustang Bio Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Earnings Documents

Mustang Bio Earnings Headlines

Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
Mustang Bio Inc.
See More Mustang Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mustang Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mustang Bio and other key companies, straight to your email.

About Mustang Bio

Mustang Bio (NASDAQ:MBIO) is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for cancer and rare genetic diseases. The company’s work centers on engineered immune-cell therapies designed to recognize and destroy cancer cells, as well as genetic medicines intended to address underlying disease causes.

Mustang’s investigational programs have included MB-106, a CD20-targeted chimeric antigen receptor T-cell (CAR-T) therapy being developed for certain B-cell malignancies, and MB-101, an IL13Rα2-targeted CAR-T therapy being studied for glioblastoma and other solid tumors. These candidates have been evaluated in clinical studies, but they are investigational and have not been established as approved treatments.

Mustang Bio was founded in 2015 and has operated as a biotechnology company affiliated with Fortress Biotech. The company has maintained research, development and manufacturing operations in the United States, including a cell- and gene-therapy manufacturing facility in Worcester, Massachusetts. Its therapies have been developed through internal research and collaborations with academic and clinical institutions.

View Mustang Bio Profile